Recruiting
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source
Contact: Robert Metcalf, MD (principal investigator)
Recruiting
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
NCT07440290· Phase 2/3· Cancer Research UK· Source
Contact: Matthew Krebs, Prof
Recruiting
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.
NCT05770544· Phase 2/3· Cancer Research UK· Source
Contact: Matthew Krebs, Dr
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232· Phase 1/2· BioNTech SE· Source
Recruiting
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
NCT06827236· Phase 1/2· BioNTech SE· Source
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007· Phase 3· Daiichi Sankyo· Source
Recruiting
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
NCT06556563· Phase 3· NovoCure GmbH· Source
Active, not recruiting
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824· Phase 3· Genmab· Source
Recruiting
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
NCT06988475· Phase 2/3· Cancer Research UK· Source
Contact: Matthew Krebs, Dr
Recruiting
Personalized Medicine for Advanced Biliary Cancer Patients
NCT05615818· Phase 3· UNICANCER· Source
Contact: Mairead MCNAMARA, MD
Active, not recruiting
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733· Phase 3· Ivy Brain Tumor Center· Source
Recruiting
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
NCT06045910· Phase 1/2· Cancer Research UK· Source
Contact: Adam Gibb, Dr
Recruiting
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
NCT05770037· Phase 2/3· Cancer Research UK· Source
Contact: Matthew Krebs, Dr
Active, not recruiting
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
NCT05004064· Phase 2· University College, London· Source
Recruiting
DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition
NCT05770102· Phase 2/3· Cancer Research UK· Source
Contact: Matthew Krebs, Dr
Recruiting
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
HTL0039732 in Participants With Advanced Solid Tumours
NCT05944237· Phase 1/2· Cancer Research UK· Source
Contact: Natalie Cook, Dr
Recruiting
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
NCT05967143· Sirtex Medical· Source
Contact: Saifee Mullamitha (principal investigator)
Recruiting
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT05786716· Phase 2/3· Cancer Research UK· Source
Contact: Matthew Krebs, Dr
Recruiting
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
NCT05722886· Phase 2/3· Cancer Research UK· Source
Contact: Matthew Krebs, Dr
Recruiting
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
NCT05768178· Phase 2/3· Cancer Research UK· Source
Contact: Matthew Krebs, Dr
Active, not recruiting
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795· Phase 3· Day One Biopharmaceuticals, Inc.· Source
Active, not recruiting
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
NCT05315258· Phase 2· University of Oxford· Source
Active, not recruiting
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
NCT05338970· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
NCT05057013· Phase 1/2· Cancer Research UK· Source
Active, not recruiting
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
NCT04546620· Phase 2· University Hospital Southampton NHS Foundation Trust· Source
Active, not recruiting
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004· Phase 2· Daiichi Sankyo· Source
Active, not recruiting
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347· Phase 1/2· Genmab· Source
Recruiting
Study to Evaluate the Safety and Tolerability of EP0042
NCT04581512· Phase 1/2· Ellipses Pharma· Source
Contact: Clinical Trials Team
Recruiting
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
NCT04068597· Phase 1/2· CellCentric Ltd.· Source
Contact: Tim Somervaille
Active, not recruiting
Stereotactic Body Radiotherapy for the Treatment of OPD
NCT03256981· Phase 2/3· Institute of Cancer Research, United Kingdom· Source
Active, not recruiting
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
NCT02406222· Phase 2· University of Leeds· Source